Clinical trials: Giant Lymph Node Hyperplasia
Idiopathic Multicentric Castleman's Disease
Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)
Development, validation of a novel symptom burden scale to assess and quantify the burden experienced by people living with Idiopathic Multicentric Castleman Disease (iMCD).
- Trial name
- NCT05995834
- Testing
- Research questions
- Volunteers
- 100 people
- Sponsor
- RECORDATI GROUP
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Background: The chemotherapy combination DA-EPOCH-RP includes the drugs etoposide (E), prednisone (P), vincristine (O), cyclophosphamide (C), doxorubicin (H), rituximab (R), and pomalidomide (P).
- Trial name
- NCT02228512
- Testing
- Pomalidomide, Rituximab, Prednisone
- Sponsor
- National Cancer Institute (NCI)
Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers.
- Conditions
- Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT05663502
- Testing
- Biospecimen Collection
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- AIDS Malignancy Consortium
Idiopathic Multicentric Castleman's Disease
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
This study is a single-arm, open-label, multicenter, dose-escalation clinical study. Its primary purpose is to evaluate the safety and tolerability of recombinant humanized anti-interleukin-6 receptor monoclonal antibody …
- Trial name
- NCT05345522
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Beijing VDJBio Co., LTD.
Lymphoma, Non-Hodgkin, Multiple Myeloma
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
- Trial name
- NCT00412321
- Testing
- CNTO 328
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Centocor, Inc.
Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
This phase I trial studies how well rituximab hyaluronidase and combination chemotherapy work in treating patients in Uganda with Burkitt lymphoma, diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated…
- Conditions
- Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03864419
- Testing
- Rituximab and Hyaluronidase Human, Cyclophosphamide, Vincristine
- Where
- Uganda
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Hereditary Autoinflammatory Diseases, Schnitzler Syndrome
AutoInflammatory Disease Alliance Registry (AIDA)
Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system.
- Conditions
- Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome
- Trial name
- AIDA (NCT05200715)
- Testing
- No intervention is foreseen by the protocol.
- Where
- 112 sites in Algeria, Australia and 20 more
- Volunteers
- 3,500 people
- Sponsor
- University of Siena
Castleman Disease, Angiofollicular Lymphoid Hyperplasia
Unlock the Cell: Castleman's Disease Flow Cytometry Study
Castleman disease, a rare lymphoproliferative disorder, is characterized by inflammatory cytokine production and multiple organ system dysfunction.
- Conditions
- Castleman Disease, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia
- Trial name
- NCT02853968
- Testing
- Blood draw/buccal swab
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Multicentric Castleman Disease
TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
To explore the effectiveness and safety of thalidomide, cyclophosphamide and prednisone (TCP regimen) in newly diagnosed Multicentric Castleman's disease (MCD) patients.
- Trial name
- NCT03043105
- Testing
- Thalidomide, cyclophosphamide and prednisone
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
Castleman Disease, Castleman's Disease
International Registry for Patients With Castleman Disease
The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.
- Conditions
- Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia
- Trial name
- ACCELERATE (NCT02817997)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH)
Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
The purpose of this study is to use agnostic genomic evaluation using whole exome sequencing (WES) of a variety of rare hematologic diseases grouped under rare blood diseases and its variants to further elucidate the…
- Conditions
- Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH), Non-Langerhans-Cell Histiocytosis
- Trial name
- NCT05028621
- Testing
- Genetic testing
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
The goals of this study is to determine if nelfinavir can target Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) in patients with certain cancers.
- Conditions
- Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Kaposi Sarcoma, Gastric Cancer
- Trial name
- NCT02080416
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Castleman Disease
Nintedanib Treatment in Unicentric Castleman Disease
Unicentric Castleman Disease (UCD) is a rare non-malignant localised disease involving one or more lymph nodes, associating germinal centre atrophy, mantle zone thickening and intense vascular proliferation penetrating the…
- Trial name
- NUCastle (NCT06643091)
- Testing
- Nintedanib
- Volunteers
- 13 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Multiple Myeloma and Plasma Cell Neoplasm
Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients who have refractory or…
- Trial name
- NCT00002652
- Testing
- suramin
- Where
- United States
- Sponsor
- University of Arkansas
Castleman Disease, Castleman's Disease
Castleman Disease Collaborative Network Biobank
The purpose of this study is to create a biobank, which collects, stores, and distributes samples of human tissues, blood, and related health information to qualified scientists, in order to help doctors and researchers better…
- Conditions
- Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia
- Trial name
- "Castlebank" (NCT02871050)
- Testing
- Sample Collection
- Where
- United States
- Sponsor
- Castleman Disease Collaborative Network
Human Immunodeficiency Virus, Castleman's Disease
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
Background: A person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes.
- Conditions
- Human Immunodeficiency Virus, Castleman's Disease, Kaposi's Sarcoma, Viral-Associated Cancer
- Trial name
- NCT03300830
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- National Cancer Institute (NCI)
Idiopathic Multicentric Castleman's Disease
Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial
To explore the effectiveness and safety of Zanuburutinib in relapsed and refractory idiopathic Multicentric Castleman's disease (iMCD) patients.
- Trial name
- iMCD (NCT04743687)
- Testing
- Zanubrutinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease
Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis
Background: Some people with human immunodeficiency virus (HIV) are on antiretroviral therapy (ART). Their cells have shown to age faster than expected.
- Conditions
- Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease, Primary Effusion Lymphoma, IL-6 Related KSHV Associated Cytokine Syndrome
- Trial name
- NCT04742387
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi Sarcoma
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Background: Kaposi sarcoma (KS) is a cancer most often seen in people with HIV. It causes lesions. These are usually on the skin but sometimes in the lymph nodes, lungs, and gastrointestinal tract.
- Trial name
- NCT02659930
- Testing
- liposomal doxorubicin, pomalidomide
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)